Tirzepatide linked to complicated diverticulitis with liver abscesses after 25 kg rapid weight loss | Research

The takeaway

A 53-year-old man on tirzepatide developed severe sepsis from sigmoid stricture, obstructive diverticulitis, and hepatic abscesses after 25 kg rapid weight loss, with reduced colonic motility and altered microbiota proposed as mechanisms.

New high-risk subgroup identified
Patients with pre-existing diverticular disease may be at risk for complicated diverticulitis during GLP-1 therapy due to reduced colonic motility and microbiota changes

What the researchers found

Age 53; pre-existing asymptomatic diverticular disease. Tirzepatide → 25 kg rapid weight loss → sigmoid stricture, obstructive diverticulitis, hepatic abscesses, severe sepsis, multi-organ dysfunction. Proposed: ↓colonic motility, altered bile, microbiota changes, bacterial translocation.

Why it matters

Diverticular disease is extremely common (>50% by age 60). If GLP-1 drugs can exacerbate it through motility effects, this represents a significant safety consideration for a large patient population.

How the study worked

Single case report with imaging and clinical documentation.

What this study cannot tell us

Single case. Diverticulitis could be coincidental. Pre-existing diverticular disease may have progressed independently. Cannot establish causation.

How to read the evidence

Single case report. Important safety signal for a common comorbidity.

When this study was published

Published in 2025.

The bigger picture

GLP-1 drugs' GI motility effects have consequences beyond nausea. Colonic motility reduction in patients with diverticular disease may create dangerous conditions for bacterial overgrowth and abscess formation.

Questions still open

Should patients with diverticular disease be screened before starting GLP-1 drugs?
Does GLP-1-induced colonic motility reduction increase diverticulitis risk?
Should rapid weight loss pace be limited in patients with diverticular disease?

Common questions

Can GLP-1 drugs worsen diverticular disease?

This case suggests they might. A patient with pre-existing diverticular disease developed severe complications (bowel stricture, liver abscesses) while on tirzepatide. GLP-1 drugs slow gut motility, which could promote bacterial overgrowth in existing diverticula. However, this is a single case and causation is not proven.

Should I tell my doctor about diverticular disease before starting a GLP-1 drug?

Yes—this is important medical information. While diverticular disease is common and most patients on GLP-1 drugs will be fine, your doctor should know about it to monitor for symptoms and consider the potential interaction between reduced gut motility and existing diverticula.

Read the original research

Diverticular Stricture and Hepatic Abscess Formation During Tirzepatide Therapy for Obesity.

Cureus, 17(11), e96564

View on PubMed ↗Publisher’s paper ↗

Citation

Taylor, Bethany; Farley-Hills, Edward; Yang, Wah; Pouwels, Sjaak; Whiteley, Graham; Wilkinson, Danielle; Agarwal, Anurag; Al-Ardah, Mahmoud; Beamish, Andrew; Hammoda, Mohammed; Hoffmann, Rebecca V; Ahmed, Ahmed; Ahmad, Suhaib. (2025). Diverticular Stricture and Hepatic Abscess Formation During Tirzepatide Therapy for Obesity.. Cureus, 17(11), e96564. https://doi.org/10.7759/cureus.96564